# SomaServe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/somaserve

- Industry: Pharmaceuticals
- Headquarters: Cambridge, UK
- Website: www.somaserve.com/
- Total disclosed funding: $28M
- Latest round: Series A (Nov 13, 2023)
- Investors on record: 8

## About

SomaServe, Ltd is a biotechnology company focused on developing advanced genetic therapies utilizing its proprietary technologies for precise delivery of nucleic acid therapeutics to address previously untreatable diseases.Founded in 2018 and headquartered in Cambridge, UK, SomaServe, Ltd specializes in the creation of genetic nanomedicines. The company has executed a total of three deals to date, with its most recent funding round being a Series A that raised USD 25.00 mn on November 13, 2023. The investment was led by 4BIO Capital Partners, Cystic Fibrosis Foundation, Eli Lilly & Company, and others. Francesca Crawford serves as the CEO.SomaServe, Ltd focuses on developing genetic nanomedicines primarily through its proprietary polyNaut® platform. This technology enables the creation of non-immunogenic nanovesicles for the targeted delivery of genetic therapies, including mRNA, siRNA, and gene editing, directly to tissues and cells. Its products cater to pharmaceutical companies and research institutions aiming to enhance the efficacy and safety of therapeutic pipelines, especially in North America and Europe.SomaServe, Ltd generates revenue by forming strategic collaborations with biotech and pharmaceutical firms, facilitating the co-development of products through its polyNaut® platform. Revenue is derived from project-based transactions, including payments for research and development services, milestone achievements, and licensing fees. Additionally, potential royalties and profit-sharing agreements are integrated into these partnerships, ensuring ongoing revenue as products are commercialized.In the wake of the USD 25.00 mn raised in Series A funding in November 2023, SomaServe, Ltd plans to leverage this capital to accelerate the development of new genetic therapies. The company seeks to expand its market presence across North America and Europe, where demand for genetic therapies is growing. Furthermore, ongoing efforts are being made to design innovative products that will be launched in the upcoming years, enhancing its portfolio and strengthening its position in the biotechnology landscape.

## Funding rounds

- Series A, Nov 13, 2023, $25M — Cystic Fibrosis Foundation, Eli Lilly & Company, 4BIO Capital Partners, O2h Ventures, UCB Ventures, Origin Capital, Meltwind
- Series A, Jan 29, 2021, $3M — Abcam plc, O2h Ventures, Origin Capital, Meltwind
- Seed, Jun 15, 2020 — O2h Ventures

## Investors

- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Seed, Series A
- Abcam plc — Series A
- Origin Capital — Series A
- Meltwind — Series A
- Cystic Fibrosis Foundation — Series A
- Eli Lilly & Company — Series A
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series A
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A